| Contents per vial | 10 mg |
|---|---|
| Form | Lyophilized powder |
| Packaging | Sealed glass vial |
| Purity | 99 % (HPLC) |
| Storage | 2–8 °C, keep dry and protect from light |
| Molecular formula | C221H342N46O68 |
| Molecular weight | 4731,33 g/mol |
| Sequence or structure | Modified peptide with 39 amino acids, an amidated C-terminus and a lipid side chain derived from a C20 diacid. Contains Aib and alpha-methylleucine |
| CAS | 2381089-83-2 |
| Intended use | For laboratory research only |
About this product
Retatrutide is an experimental peptide and triple agonist of GLP-1, GIP and glucagon receptors. This combination distinguishes it from drugs acting only on GLP-1 or on GLP-1/GIP. Clinical research focuses mainly on obesity, weight management, appetite control and metabolic health. Significant weight loss and improvement in several metabolic indicators were observed in studies. Retatrutide is therefore among the most prominently investigated new incretin molecules.
What is RETATRUTIDE?
RETATRUTIDE is characterized in this portfolio as a synthetic peptide or peptide analog intended for controlled laboratory investigation. Scientific interest is focused on body weight regulation, control of appetite and satiety, glycemia and insulin, cardiometabolic indicators and related biochemical or receptor processes. Changes in predetermined markers, functional responses and signaling pathways are compared in experimental protocols.
Mechanism of action under investigation
Retatrutide simultaneously activates GLP-1, GIP and glucagon receptors. GLP-1/GIP pathways promote satiety and glucose-dependent insulin response; the glucagon component can increase energy expenditure and affect fat metabolism. The result is a combined effect on appetite, energy intake and metabolic balance.
MAIN AREAS OF RESEARCH
• Body weight regulation: Research focuses on significant changes in body weight and energy balance that are related to the simultaneous activation of GIP, GLP-1 and glucagon receptors.
• Appetite and satiety control: Retatrutide’s triple receptor signaling is being investigated for effects on food intake, satiety, and mechanisms that influence long-term weight management.
• Glycemic control: Clinical research monitors HbA1c, fasting glucose and insulin response, as the GIP and GLP-1 component directly intervenes in blood sugar regulation.
• Cardiometabolic indicators: In addition to weight, waist circumference, blood pressure and blood lipids are also monitored, providing a broader picture of metabolic changes during research on Retatrutide.
• Fat stored in the liver: Separate clinical analyses evaluate changes in the amount of liver fat using imaging methods, particularly in people with obesity and metabolic disorders.
Research findings to date
Work to date with RETATRUTIDE has focused on areas including body weight regulation, appetite and satiety control, glycemia and insulin, cardiometabolic indicators, and liver fat. Clinical research focuses mainly on obesity, weight management, appetite control and metabolic health. Significant weight loss and improvement in several metabolic indicators were observed in studies.
In clinical studies, the most common side effects were gastrointestinal problems, such as nausea, diarrhea, vomiting, or constipation. Changes in appetite and other metabolic effects may also occur. As retatrutide is still an investigational substance, its long-term safety profile is being further evaluated.
